Regor Signs Purchase Agreement for Genentech to Acquire CDK Inhibitors for Breast Cancer

Genentech has announced plans to acquire a portfolio of next-generation CDK inhibitors from Regor Pharmaceuticals (USA) for treating breast cancer. The purchase agreement stipulates that Regor will receive an upfront payment of $850 million in cash, with the possibility of additional payments contingent on reaching specific development, regulatory, and commercial milestones.

Genentech, a member of the Roche Group, will take on the global responsibilities for clinical development, manufacturing, and commercialization of these CDK inhibitors. Regor will continue to oversee the completion of its ongoing Phase 1 trials, while also pushing forward with its other ventures in oncology, metabolic diseases, and autoimmune disorders.

Dr. Xiayang Qiu, founder and CEO of Regor, expressed optimism about the collaboration, highlighting Genentech's capability to maximize the potential of these novel treatments for breast cancer patients globally. Qiu also emphasized Regor’s commitment to developing innovative therapies, buoyed by the promising data they’ve achieved thus far.

The transaction is expected to be finalized in the fourth quarter of 2024, pending the satisfaction of customary closing conditions. BofA Securities, Inc. is acting as the exclusive financial advisor for Regor in this transaction, with Cohen, Tauber Spievack & Wagner PC and DLA Piper serving as legal advisors.

Regor Pharmaceuticals (USA) operates under Regor Therapeutics Group, a biotechnology firm focused on creating innovative and distinct therapies for significant unmet needs in oncology, metabolism, and auto-immunity. Through its proprietary CARD (Computer Accelerated Rational Discovery) Platform, Regor has advanced numerous in-house discovered assets into various stages of preclinical and clinical development, validating its highly efficient discovery ecosystem for new therapeutic agents.